Eleven Biotherapeutics (EBIO) Reports Q1 Loss of $0.25

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q1 EPS of ($0.25), versus ($0.39) reported last year. Revenue for the quarter came in at $400 thousand, versus $200 thousand reported last year.

Cash Position: Cash and cash equivalents were $20.3 million as of March 31, 2017, compared to $25.3 million as of December 31, 2016.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Moody’s raises BJ’s Wholesale outlook to positive on debt reduction
• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance